Adeno‐associated Viral Vectors in Gene Therapy

Abstract

Recombinant vectors based on a nonpathogenic human parvovirus, the Adeno‐associated virus 2 (AAV), have gained attention as a potentially safe and useful alternative to the more commonly used retroviral and adenoviral vectors. AAV vectors are currently in use in phase I/II clinical trials for gene therapy of a number of diseases such as cystic fibrosis, α‐1 antitrypsin deficiency, muscular dystrophy, Batten disease and Parkinson disease. Several salient features of AAV vectors and the availability of promising results with animal models of human diseases provide the impetus to suggest that they will be used in potential gene therapy of a number of human diseases, both genetic and acquired, in not too distant a future.

Keywords: AAV; viral vectors; gene expression; gene therapy

Figure 1.

Schematic structures of a conventional, single‐stranded (ss) and a double‐stranded (ds), self‐complementary AAV vector. The approximate packaging capacity of each vector is also indicated.

close

References

Acland GM, Aguirre GD, Ray J et al. (2001) Gene therapy restores vision in a canine model of childhood blindness. Nature Genetics 28: 92–95.

Beaty RM, Jackson M, Peterson D et al. (2001) Delivery of glucose‐6‐phosphatase in a canine model for glycogen storage disease, type Ia, with adeno‐associated virus (AAV) vectors. Gene Therapy 9: 1015–1022.

Berns KI and Giraud C (1996) Adeno‐associated virus (AAV) vectors in gene therapy. Current Topics in Microbiology and Immunology 218: 1–170.

Carter BJ (2005) Adeno‐associated virus vectors in clinical trials. Human Gene Therapy 16: 541–550.

Chen Y, Luk KD, Cheung KM et al. (2003) Gene therapy for new bone formation using adeno‐associated viral bone morphogenetic protein‐2 vectors. Gene Therapy 10: 1345–1353.

Chiorini JA, Kim F, Yang L and Kotin RM (1999) Cloning and characterization of adeno‐associated virus type 5. Journal of Virology 73: 1309–1319.

Chiorini JA, Yang L, Liu Y, Safer B and Kotin RM (1997) Cloning of adeno‐associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. Journal of Virology 71: 6823–6833.

Crystal RG, Sondhi D, Hackett NR et al. (2004) Clinical protocol. Administration of a replication‐deficient adeno‐associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Human Gene Therapy 15: 1131–1154.

Deodato B, Arsic N, Zentilin L et al. (2002) Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Therapy 9: 777–785.

Donsante A, Vogler C, Muzyczka N et al. (2001) Observed incidence of tumorigenesis in long‐term rodent studies of rAAV vectors. Gene Therapy 8: 1343–1346.

Dumon KR, Ishii H, Vecchione A et al. (2001) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Research 61: 4827–4836.

During MJ, Kaplitt MG, Stern MB and Eidelberg D (2001) Subthalamic GAD gene transfer in Parkinson’ disease patients who are candidates for deep brain stimulation. Human Gene Therapy 12: 1589–1591.

During MJ, Samulski RJ, Elsworth JD et al. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP‐treated monkeys using an AAV vector. Gene Therapy 5: 820–827.

During MJ, Symes CW, Lawlor PA et al. (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287: 1453–1460.

Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J and Oudega M (2002) Amelioration of chronic neuropathic pain after partial nerve injury by adeno‐associated viral (AAV) vector‐mediated over‐expression of BDNF in the rat spinal cord. Gene Therapy 9: 1387–1395.

Ferrarini M, Arsic N, Recchia FA et al. (2006) Adeno‐associated virus‐mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circulation Research 98: 954–961.

Flotte T, Carter B, Conrad C et al. (1996) A phase I study of an adeno‐associated virus‐CFTR gene vector in adult CF patients with mild lung disease. Human Gene Therapy 7: 1145–1159.

Flotte TR, Brantly ML, Spencer LT et al. (2004) Phase I trial of intramuscular injection of a recombinant adeno‐associated virus alpha 1‐antitrypsin (rAAV2‐CB‐hAAT) gene vector to AAT‐deficient adults. Human Gene Therapy 15: 93–128.

Fraites TJ Jr, Schleissing MR, Shanely RA et al. (2002) Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno‐associated virus vectors. Molecular Therapy 5: 571–578.

Frisella WA, O’Connor LH, Vogler CA et al. (2001) Intracranial injection of recombinant adeno‐associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Molecular Therapy 3: 351–358.

Gao G, Alvira MR, Wang L et al. (2002) Novel adeno‐associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences of the USA 99: 11854–11859.

Gao G, Vandenberghe LH, Alvira MR et al. (2004) Clades of adeno‐associated viruses are widely disseminated in human tissues. Journal of Virology 78: 6381–6388.

Grieger JC, Choi VW and Samulski RJ (2006) Production and characterization of adeno‐associated viral vectors. Nature Protocols 1: 1412–1428.

Griffey MA, Wozniak D, Wong M et al. (2006) CNS‐directed AAV2‐mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Molecular Therapy 13: 538–547.

Haberman RP, Samulski RJ, McCown TJ et al. (2003) Attenuation of seizures and neuronal death by adeno‐associated virus vector galanin expression and secretion. Nature Medicine 9: 1076–1080.

Hengge UR and Mirmohammadsadegh A (2000) Adeno‐associated virus expresses transgenes in hair follicles and epidermis. Molecular Therapy 2: 188–194.

Hoshijima M, Ikeda Y, Iwanaga Y et al. (2002) Chronic suppression of heart‐failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nature Medicine 8: 864–871.

Janson C, McPhee S, Bilaniuk L et al. (2002) Clinical protocol. Gene therapy of Canavan disease: AAV‐2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Human Gene Therapy 13: 1391–1412.

Kaplitt MG, Leone P, Samulski RJ et al. (1994) Long‐term gene expression and phenotypic correction using adeno‐associated virus vectors in the mammalian brain. Nature Genetics 8: 148–154.

Kaplitt MG, Xiao X, Samulski RJ et al. (1996) Long‐term gene transfer in porcine myocardium after coronary infusion of an adeno‐associated virus vector. Annals of Thoracic Surgery 62: 1669–1676.

Kay MA, Manno CS, Ragni MV et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics 24: 257–261.

Kessler PD, Podsakoff GM, Chen X et al. (1996) Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proceedings of the National Academy of Sciences of the USA 93: 14 082–14 087.

Kotin RM, Siniscalco M, Samulski RJ et al. (1990) Site‐specific integration by adeno‐associated virus. Proceedings of the National Academy of Sciences of the USA 87: 2211–2215.

Kunke D, Grimm D, Denger S et al. (2000) Preclinical study on gene therapy of cervical carcinoma using adeno‐associated virus vectors. Cancer Gene Therapy 7: 766–777.

Lalani AS, Chang B, Lin J et al. (2004) Anti‐tumor efficacy of human angiostatin using liver‐mediated adeno‐associated virus gene therapy. Molecular Therapy 9: 56–66.

Lalwani AK, Walsh BJ, Reilly PG, Muzyczka N and Mhatre AN (1996) Development of in vivo gene therapy for hearing disorders: introduction of adeno‐associated virus into the cochlea of the guinea pig. Gene Therapy 3: 588–592.

Lee HC, Kim S‐J, Kim K‐S, Shin H‐C and Yoon J‐W (2000) Remission in models of type 1 diabetes by gene therapy using a single‐chain insulin analogue. Nature 408: 483–488.

Leone P, Janson CG, Bilaniuk L et al. (2000) Aspartocyclase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Annals of Neurology 48: 27–38.

Li J, Dressman D, Tsao YP et al. (1999) Recombinant AAV vector‐mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Therapy 6: 74–82.

Ma H, Guo P, Li J et al. (2002) Suppression of intracranial human glioma growth after intramuscular administration of an adeno‐associated viral vector expressing angiostatin. Cancer Research 62: 756–763.

Ma H, Xu R, Cheng H et al. (2003) Gene transfer into human keloid tissue with adeno‐associated virus vector. Journal of Trauma 54: 569–573.

McBride JL, During MJ, Wuu J et al. (2003) Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Experimental Neurology 181: 213–223.

Mease PJ (2003) A phase I dose escalation study of intra‐articular administration of tgAAC94, a recombinant adeno‐associated virus containing the TNFR:Fc fusion gene, in rheumatoid arthritis. NIH Recombinant DNA advisory Committee, Minutes of Meeting of September, 2003. Available at URL www.od.nih.gov/oba/RAC/meeting.html.

Mori S, Wang L, Takenchi T and Kanda T (2004) Two novel adeno‐associated viruses from cynomolgus monkey pseudotyping characterization of capsid protein. Virology 330: 375–383.

Muramatsu S, Mizukami H, Young NS and Brown KE (1996) Nucleotide sequencing and generation of an infectious clone of adeno‐associated virus 3. Virology 221: 208–217.

Murphy JE, Zhou S, Giese K et al. (1997) Long‐term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno‐associated virus encoding mouse leptin. Proceedings of the National Academy of Sciences of the USA 94: 13921–13926.

Muzyczka N (1992) Use of adeno‐associated virus as a general transduction vector for mammalian cells. Current Topics in Microbiology and Immunology 158: 97–129.

Muzyczka N and Berns KI (2001) In: Knipe D, Howley P and Griffin D et al. (eds) Fields’ Virology. Philadelphia, PA: Lippincott, Williams & Wilkins.

Narfstrom K, Bragadottir R, Redmond TM et al. (2003) Functional and structural evaluation after AAV.RPE65 gene transfer in the canine model of Leber's congenital amaurosis. Advances in Experimental Medicine and Biology 533: 423–430.

Pan RY, Xiao X, Chen SL et al. (1999) Disease‐inducible transgene expression from a recombinant adeno‐associated virus vector in a rat arthritis model. Journal of Virology 73: 3410–3417.

Ponnazhagan S, Mukherjee P, Yoder MC et al. (1997) Adeno associated virus 2‐mediated gene transfer in vivo: organ‐tropism and expression of transduced sequences in mice. Gene 190: 203–210.

Qing KY, Mah C, Hansen J et al. (1999) Human fibroblast growth factor receptor 1 is a co‐receptor for infection by adeno‐associated virus 2. Nature Medicine 5: 71–77.

Rehman KK, Wang Z, Bottino R et al. (2005) Efficient gene delivery to human and rodent islets with double‐stranded (ds) AAV‐based vectors. Gene Therapy 12: 1313–1323.

Ross CJ, Twisk J, Meulenberg JM et al. (2004) Long‐term correction of murine lipoprotein lipase deficiency with AAV1‐mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Human Gene Therapy 15: 906–919.

Ruitenberg MJ, Blits B, Dijkhuizen PA et al. (2004) Adeno‐associated viral vector‐mediated gene transfer of brain‐derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury. Neurobiology of Disease 15: 394–406.

Rutledge EA, Halbert CL and Russell DW (1998) Infectious clones and vectors derived from adeno‐associated virus (AAV) serotypes other than AAV type 2. Journal of Virology 72: 309–319.

Samulski RJ, Zhu X, Xiao X et al. (1991) Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. European Molecular Biology Organization Journal 10: 3941–3950.

Sarkar R, Xiao W and Kazazian HH Jr (2003) A single adeno‐associated virus (AAV)‐murine factor VIII vector partially corrects the hemophilia A phenotype. Journal of Thrombosis and Haemostasis 1: 220–226.

Schmidt M, Voutetakis A, Afione S, Zheng C and Chiorini JA (2006) AAV12, isolated from vervet monkey, has unique tropism and biological as well as neutralization properties. Molecular Therapy 13: S288.

Song S, Morgan M, Ellis T et al. (1998) Sustained secretion of human α‐1‐antitrypsin from murine muscle transduced with adeno‐associated virus vectors. Proceedings of the National Academy of Sciences of the USA 95: 14384–14388.

Srivastava A, Lusby EW and Berns KI (1983) Nucleotide sequence and organization of the adeno‐associated virus 2 genome. Journal of Virology 45: 555–564.

Stedman H, Mendell J, Wilson JM, Finke R and Kleckner A‐L (2000) Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α‐, β‐, γ‐, or Δ‐sarcoglycan gene delivered with intramuscular instillations of adeno‐associated vectors. Human Gene Therapy 11: 777–790.

Su H, Chang JC, Xu SM and Kan YW (1996) Selective killing of AFP‐positive hepatocellular carcinoma cells by adenoassociated virus transfer of the herpes simplex virus thymidine kinase gene. Human Gene Therapy 7: 463–470.

Summerford C, Bartlett JS and Samulski RJ (1999) αVβ5 integrin: a co‐receptor for adeno‐associated virus 2 infection. Nature Medicine 5: 78–81.

Summerford C and Samulski RJ (1998) Membrane‐associated heparan sulfate proteoglycan is a receptor for adeno‐associated type 2 virions. Journal of Virology 72: 1438–1445.

Sun JY, Chatterjee S and Wong KK (2002) Immunogenic issues concerning recombinant adeno‐associated virus vectors for gene therapy. Current Gene Therapy 2: 485–500.

Tan MQ, Qing KY, Zhou SZ, Yoder MC and Srivastava A (2001) Adeno‐associated virus 2‐mediated transduction and erythroid lineage‐restricted long‐term expression of the human β‐globin gene in hematopoietic cells from homozygous β‐thalassemic mice. Molecular Therapy 3: 940–946.

Tuszynski MH, Thal L, Pay M et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine 11: 551–555.

Wagner J, Reynolds T, Moran ML et al. (1998) Efficient and persistent gene transfer of AAV‐CFTR in maxillary sinus. Lancet 351: 1702–1703.

Wang B, Li J and Xiao X (2000) Adeno‐associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proceedings of the National Academy of Sciences of the USA 97: 13714–13719.

Wang LJ, Lu YY, Muramatsu S et al. (2002) Neuroprotective effects of glial cell line‐derived neurotrophic factor mediated by an adeno‐associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. The Journal of Neuroscience 22: 6920–6928.

Wang X‐S, Ponnazhagan S and Srivastava A (1996) Rescue and replication of adeno‐associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. Journal of Virology 70: 1668–1677.

Watanabe M, Nasu Y, Kashiwakura Y et al. (2005) Adeno‐associated virus 2‐mediated intratumoral prostate cancer gene therapy: long‐term maspin expression efficiently suppresses tumor growth. Human Gene Therapy 16: 699–710.

Wei X, Zhao C, Jiang J et al. (2005) Adrenomedullin gene delivery alleviates hypertension and its secondary injuries of cardiovascular system. Human Gene Therapy 16: 372–380.

Xiao W, Chirmule N, Berta SC et al. (1999) Gene therapy vectors based on adeno‐associated virus type 1. Journal of Virology 73: 3994–4003.

Xin K‐Q, Urabe M, Yang J et al. (2001) A novel recombinant adeno‐associated virus vaccine induces a long‐term humoral immune response to human immunodeficiency virus. Human Gene Therapy 12: 1047–1061.

Yasukawa H, Yajima T, Duplain H et al. (2003) The suppressor of cytokine signaling‐1 (SOCS1) is a novel therapeutic target for enterovirus‐induced cardiac injury. The Journal of Clinical Investigation 111: 469–478.

Yoshioka T, Okada T, Maeda Y et al. (2004) Adeno‐associated virus vector‐mediated interleukin‐10 gene transfer inhibits atherosclerosis in apolipoprotein E‐deficient mice. Gene Therapy 11: 1772–1779.

Zhang J, Wu X, Qin C et al. (2003) A novel recombinant adeno‐associated virus vaccine reduces behavioral impairment and beta‐amyloid plaques in a mouse model of Alzheimer's disease. Neurobiology of Disease 14: 365–379.

Further Reading

Herzog RW (2007) Immune responses to AAV capsid: are mice not humans after all? Molecular Therapy 15: 649–650.

Kaplitt MG, Feigin A, Tang C et al. (2007) Safety and tolerability of gene therapy with an adeno‐associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097–2105.

Li C, Hirsch M, Asokan A et al. (2007) Adeno‐associated virus type 2 (AAV2) capsid‐specific cytotoxic T lymphocytes eliminate only vector‐transduced cells coexpressing the AAV2 capsid in vivo. Journal of Virology 81: 7540–7547.

Li H, Murphy SL, Giles‐Davis W et al. (2007) Pre‐existing AAV capsid‐specific CD8+ T cells are unable to eliminate AAV‐transduced hepatocytes. Molecular Therapy 15: 792–800.

Mandel RJ and Burger C (2004) Clinical trials in neurological disorders using AAV vectors: promises and challenges. Current Opinion in Molecular Therapy 6: 482–490.

Manno CS, Pierce GF, Arruda VR et al. (2006) Successful transduction of liver in hemophilia by AAV‐Factor IX and limitations imposed by the host immune response. Nature Medicine 12: 342–347.

Mingozzi F, Maus MV, Hui DJ et al. (2007) CD8(+) T‐cell responses to adeno‐associated virus capsid in humans. Nature Medicine 13: 419–422.

Phillips MI (1997) Antisense inhibition and adeno‐associated viral vector delivery for reducing hypertension. Hypertension 29: 177–187.

Raol YH, Lund IV, Bandyopadhyay S et al. (2006) Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. The Journal of Neuroscience 26: 11342–11346.

Williams DA (2007) Of Mouse Models and Men. Molecular Therapy 15: 643.

Vandenberghe LH, Wang L, Somanathan S et al. (2007) Heparin binding directs activation of T cells against adeno‐associated virus serotype 2 capsid. Nature Medicine 12: 967–971.

Wu J, Zhao W, Zhong L et al. (2007) Self‐ complementary recombinant adeno‐associated virus vectors: packaging capacity and the role of rep proteins in vector purity. Human Gene Therapy 18: 171–182.

Zhao W, Wu J, Zhong L and Srivastava A (2007) Adeno‐associated virus 2‐mediated gene transfer: identification of a cellular protein serine/threonine phosphatase involved in augmenting vector transduction efficiency. Gene Therapy 14: 545–550.

Zhong L, Zhao W, Wu J et al. (2006) Adeno‐associated virus‐mediated gene transfer in hematopoietic stem/progenitor cells as a therapeutic tool. Current Gene Therapy 6: 683–698.

Zhong L, Zhao W, Wu J et al. (2007) A dual role of epidermal growth factor receptor protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second‐strand DNA synthesis. Molecular Therapy 15: 1323–1330.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Zhong, Li, and Srivastava, Arun(Sep 2007) Adeno‐associated Viral Vectors in Gene Therapy. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0005738.pub2]